insiderwall
Menu
SuperinvestorInsider
Myriad Genetics Inc. MYGN

Super Investor & Insider

Nessuna transazione insider negli ultimi 6 mesi.

Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.

About

Myriad Genetics Inc. is a biotechnology company specializing in the development and commercialization of genetic tests that assess risk for cancer and other hereditary conditions. The company is renowned for its pioneering efforts in molecular diagnostics, offering tests that help individuals and healthcare providers m

SectorHealthcare
ExchangeNASDAQ
IndustryDiagnostics & Research
CountryUnited States
Employees2,700
TickerMYGN

Statistics

Market Cap$405.0M
Revenue (TTM)$824.5M
Net Income-$365.9M
Net Margin-44.4%
EPS$-3.95
P/E-1.11
P/S0.76
P/B1.25
EV/EBITDA-2.48
ROE-23.5%
Dividend Yield
Price$4.29

Data: Twelve Data · Revenue = mcap / P/S